Santhera Pharmaceuticals Holding Future Growth
Future criteria checks 6/6
Santhera Pharmaceuticals Holding is forecast to grow earnings and revenue by 35.4% and 26.8% per annum respectively. EPS is expected to grow by 31.4% per annum. Return on equity is forecast to be 48.6% in 3 years.
Key information
35.4%
Earnings growth rate
31.4%
EPS growth rate
| Biotechs earnings growth | 37.1% |
| Revenue growth rate | 26.8% |
| Future return on equity | 48.6% |
| Analyst coverage | Low |
| Last updated | 27 Sep 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 135 | 53 | 61 | 61 | 1 |
| 12/31/2025 | 48 | -10 | -6 | -6 | 2 |
| 12/31/2024 | 24 | -35 | -32 | -32 | 2 |
| 6/30/2024 | 114 | 63 | 24 | 47 | N/A |
| 3/31/2024 | 109 | 59 | 24 | 47 | N/A |
| 12/31/2023 | 103 | 55 | 24 | 47 | N/A |
| 9/30/2023 | 54 | -5 | -7 | 7 | N/A |
| 6/30/2023 | 5 | -65 | -37 | -33 | N/A |
| 3/31/2023 | 6 | -68 | -35 | -32 | N/A |
| 12/31/2022 | 7 | -71 | -34 | -30 | N/A |
| 9/30/2022 | 4 | -68 | -32 | -30 | N/A |
| 6/30/2022 | 0 | -65 | -31 | -31 | N/A |
| 3/31/2022 | -1 | -60 | -34 | -34 | N/A |
| 12/31/2021 | -2 | -56 | -37 | -37 | N/A |
| 9/30/2021 | 5 | -56 | -40 | -40 | N/A |
| 6/30/2021 | 12 | -56 | -42 | -42 | N/A |
| 3/31/2021 | 13 | -62 | -43 | -43 | N/A |
| 12/31/2020 | 15 | -68 | -44 | -44 | N/A |
| 9/30/2020 | 40 | -46 | -20 | -20 | N/A |
| 6/30/2020 | 65 | -24 | 3 | 3 | N/A |
| 3/31/2020 | 70 | -21 | 3 | 3 | N/A |
| 12/31/2019 | 75 | -19 | 2 | 3 | N/A |
| 9/30/2019 | 55 | -37 | -34 | -14 | N/A |
| 6/30/2019 | 34 | -54 | -56 | -36 | N/A |
| 3/31/2019 | 33 | -54 | -58 | -37 | N/A |
| 12/31/2018 | 32 | -54 | -60 | -38 | N/A |
| 9/30/2018 | 30 | -58 | -43 | -41 | N/A |
| 6/30/2018 | 28 | -56 | -45 | -42 | N/A |
| 3/31/2018 | 26 | -54 | N/A | -41 | N/A |
| 12/31/2017 | 23 | -52 | N/A | -40 | N/A |
| 9/30/2017 | 22 | -42 | N/A | -39 | N/A |
| 6/30/2017 | 23 | -40 | N/A | -33 | N/A |
| 3/31/2017 | 21 | -38 | N/A | -30 | N/A |
| 12/31/2016 | 19 | -35 | N/A | -27 | N/A |
| 9/30/2016 | 15 | -21 | N/A | -28 | N/A |
| 6/30/2016 | 10 | -6 | N/A | -29 | N/A |
| 3/31/2016 | 7 | 0 | N/A | -25 | N/A |
| 12/31/2015 | 4 | 6 | N/A | -22 | N/A |
| 9/30/2015 | 4 | -3 | N/A | -17 | N/A |
| 6/30/2015 | 3 | -11 | N/A | -11 | N/A |
| 3/31/2015 | 3 | -10 | N/A | -8 | N/A |
| 12/31/2014 | 3 | -8 | N/A | -6 | N/A |
| 9/30/2014 | 2 | -7 | N/A | -6 | N/A |
| 6/30/2014 | 1 | -6 | N/A | -5 | N/A |
| 3/31/2014 | 1 | -6 | N/A | -6 | N/A |
| 12/31/2013 | 1 | -6 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0QN1's forecast earnings growth (35.4% per year) is above the savings rate (2.1%).
Earnings vs Market: 0QN1's earnings (35.4% per year) are forecast to grow faster than the UK market (14.8% per year).
High Growth Earnings: 0QN1's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 0QN1's revenue (26.8% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0QN1's revenue (26.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0QN1's Return on Equity is forecast to be very high in 3 years time (48.6%).